Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poseltinib - Hanmi Pharmaceutical

Next Previous
Drug Profile

Poseltinib - Hanmi Pharmaceutical

Alternative Names: HM 71224; LY 3337641

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Eli Lilly and Company; Hanmi Pharmaceutical
  • Class Antirheumatics; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 08 Jun 2023 Efficacy and adverse event data from phase II trial in Diffuse large B cell lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)
  • 23 Jan 2023 Discontinued - Phase-I for Rheumatoid arthritis (In volunteers) in Netherlands, Singpaore (PO) as of January 2023 (Hanmi Pharmaceutical pipeline, January 2023; Eli lilly and company pipeline, January 2023)
  • 23 Jan 2023 Discontinued - Phase-II for Rheumatoid arthritis in Argentina, Puerto Rico, Australia, Austria, USA, Japan, South Africa, South Africa, Germany, Mexico, Poland, Slovakia, South Korea, Italy, Spain (PO) as of January 2023 (Hanmi Pharmaceutical pipeline, January 2023; Eli lilly and company pipeline, January 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top